Reported about 9 hours ago
Johnson & Johnson and Novartis are adapting their manufacturing processes to mitigate the effects of tariffs imposed by the Trump administration. Johnson & Johnson plans to invest over $55 billion in U.S. manufacturing over the next four years, while Novartis aims to invest $23 billion to ensure local production of its medicines. Both companies demonstrate financial resilience and a commitment to dividend payouts, making them attractive options for investors despite potential challenges.
Source: YAHOO